Most Dogs with Heart Disease Show No Signs Until It Is Advanced
The defining challenge of canine cardiac disease is its silence. Dogs with early mitral valve degeneration, subclinical dilated cardiomyopathy, or developing arrhythmias typically appear normal to their owners. They eat, play, and sleep as usual. By the time clinical signs emerge (coughing, exercise intolerance, labored breathing, collapse), the disease has often progressed to a stage where treatment options are limited and prognosis is guarded.
This gap between disease onset and symptom onset is exactly where screening earns its value. The EPIC study (Boswood et al., 2016) demonstrated that treating preclinical myxomatous mitral valve disease (MMVD) with pimobendan before the onset of congestive heart failure extended the time to heart failure by a median of 15 months. But that treatment window only exists if the disease is detected before symptoms appear. Without screening, the window closes silently.
Heart disease is the second leading cause of death in dogs after cancer, and for certain breeds, it is the primary cause. Structured cardiac screening by breed risk, age, and clinical indicators is one of the most evidence-backed longevity protocols available.
The Core Screening Tools
Auscultation (Stethoscope Examination)
Cardiac auscultation is the first-line screening tool at every veterinary visit. A skilled clinician can detect murmurs, arrhythmias, gallop rhythms, and abnormal lung sounds. Murmurs are graded on a I-VI scale, with grade I being barely audible and grade VI being palpable through the chest wall.
Auscultation has important limitations. It cannot determine the underlying cause of a murmur, quantify chamber enlargement, or assess systolic function. It can miss early disease: some dogs with significant cardiac pathology have no auscultable murmur, particularly in early dilated cardiomyopathy (DCM) where the primary problem is myocardial contractility rather than valve leakage.
Auscultation is a screening trigger, not a definitive diagnostic. A murmur in a middle-aged Cavalier King Charles Spaniel should prompt echocardiography, not reassurance.
Echocardiography (Cardiac Ultrasound)
Echocardiography is the gold standard for structural and functional cardiac assessment. It provides real-time visualization of:
- Chamber dimensions. Left atrial and left ventricular size indicate volume overload severity in valve disease. The left atrium-to-aorta ratio (LA:Ao) is a key parameter: ratios above 1.6 indicate significant enlargement.
- Valve function. Doppler imaging detects and quantifies regurgitant jets across incompetent valves.
- Myocardial contractility. Fractional shortening (FS%) and ejection fraction measure how effectively the heart muscle contracts. Reduced contractility is the hallmark of DCM.
- Pericardial effusion. Fluid around the heart, which can cause tamponade, is immediately visible on echo.
The ACVIM consensus (Keene et al., 2019) established echocardiographic criteria for staging MMVD in dogs, creating clear thresholds for when to initiate treatment. This staging system (B1 through D) is now the standard framework for managing the most common cardiac disease in dogs.
Electrocardiography (ECG)
ECG records the heart’s electrical activity and is the primary tool for detecting arrhythmias. While murmurs reflect structural disease, arrhythmias reflect electrical disease, and the two do not always coexist.
ECG is particularly important for breeds prone to arrhythmogenic conditions:
- Boxer: Arrhythmogenic right ventricular cardiomyopathy (ARVC) produces ventricular premature complexes (VPCs) that may be absent during a brief office ECG but detectable on 24-hour Holter monitoring.
- Doberman Pinscher: DCM frequently presents with ventricular arrhythmias before systolic dysfunction is echocardiographically apparent.
A standard office ECG captures 30-60 seconds of rhythm. For breeds with intermittent arrhythmias, a 24-hour Holter monitor (a portable ECG recorder the dog wears at home) provides dramatically better detection sensitivity. More than 50 VPCs in 24 hours is considered abnormal in most breeds and warrants further investigation.
NT-proBNP (Cardiac Biomarker)
N-terminal pro-B-type natriuretic peptide (NT-proBNP) is released by cardiac muscle cells under stretch or volume overload. Elevated levels indicate myocardial stress and correlate with disease severity.
Wess et al. (2010) demonstrated that NT-proBNP can distinguish between occult (preclinical) DCM and normal cardiac function in Doberman Pinschers with reasonable sensitivity and specificity. Oyama (2013) reviewed the broader utility of cardiac biomarkers in veterinary practice and concluded that NT-proBNP is most valuable as a screening and monitoring tool, not as a standalone diagnostic.
NT-proBNP is available as an in-clinic SNAP test or a reference laboratory assay. Its primary value is identifying dogs that warrant echocardiographic evaluation, particularly in breeds where cardiac screening compliance is low and a simple blood test may increase detection rates.
Breed-Specific Cardiac Risks and Screening Timelines
Cavalier King Charles Spaniel
Primary risk: Myxomatous mitral valve disease. Nearly 100% prevalence by age 10. Early-onset disease (by age 5) is common.
Screening protocol: Annual cardiac auscultation starting at age 1. First echocardiogram by age 3, then annually. Any murmur should trigger immediate echo regardless of age. The ACVIM consensus staging system guides treatment initiation.
See Cavalier King Charles Spaniel longevity guide.
Doberman Pinscher
Primary risk: Dilated cardiomyopathy. Prevalence estimated at 45-63% of the breed. Sudden cardiac death can occur before clinical signs of heart failure.
Screening protocol: Annual echocardiography and 24-hour Holter monitoring starting at age 3. NT-proBNP testing can supplement echo in years between full cardiac evaluations. Summerfield et al. (2012) showed that early pimobendan treatment in preclinical DCM extended survival time.
See Doberman Pinscher longevity guide.
Boxer
Primary risk: Arrhythmogenic right ventricular cardiomyopathy (ARVC), also called Boxer cardiomyopathy. Ventricular arrhythmias may cause syncope or sudden death.
Screening protocol: Annual 24-hour Holter monitoring starting at age 3. Echocardiography at baseline and when clinical concern arises. Standard office ECG misses most Boxer arrhythmias due to their intermittent nature.
Great Dane
Primary risk: Dilated cardiomyopathy. Giant breed with accelerated aging timeline.
Screening protocol: First echocardiogram by age 2-3, then annually. Any Great Dane presenting with exercise intolerance, weakness, or syncope should receive immediate cardiac workup.
Irish Wolfhound
Primary risk: Dilated cardiomyopathy and atrial fibrillation. Prevalence of DCM estimated at 24% or higher.
Screening protocol: Annual echocardiography and ECG starting at age 2. Irish Wolfhounds have a normally lower fractional shortening than smaller breeds; breed-specific reference ranges should be used for interpretation.
All Dogs (General Population)
Screening timeline: Cardiac auscultation at every veterinary visit. For any dog, a new murmur, exercise intolerance, coughing, or syncope should trigger echocardiography. For medium and large breeds, baseline echocardiography at age 7 provides early detection value, particularly for breeds without well-studied cardiac risk profiles.
Integrating Cardiac Screening Into a Longevity Protocol
Cardiac screening is most valuable as part of a broader longevity monitoring framework. See annual wellness testing protocol for guidance on age-based testing cadence.
A practical integration approach:
- Know your breed’s risk. Check whether your dog’s breed has documented cardiac predisposition and follow breed-specific screening timelines.
- Establish baseline. A baseline echocardiogram in the first half of life provides comparison data that makes future changes detectable.
- Monitor biomarkers. NT-proBNP measured annually allows trend tracking even between full echocardiographic evaluations.
- Respond to triggers. New murmur, exercise intolerance, respiratory rate increase at rest (normal is under 30 breaths per minute during sleep), coughing, or syncope should all trigger immediate evaluation, not a “wait and see” approach.
Limitations
Echocardiography is operator-dependent and requires specialized training; results vary with examiner experience. Holter monitor interpretation requires expertise in distinguishing clinically significant arrhythmias from benign variants. NT-proBNP levels can be elevated by non-cardiac conditions (renal disease, pulmonary hypertension). Breed-specific reference ranges are not established for all breeds. Screening protocols are best validated for breeds with high cardiac disease prevalence; for mixed-breed dogs and low-risk breeds, optimal screening intervals are less well-defined.
Frequently Asked Questions
At what age should I start cardiac screening for my dog?
For high-risk breeds (Cavalier King Charles Spaniel, Doberman, Boxer, Great Dane, Irish Wolfhound), screening should begin between ages 1 and 3 depending on the breed-specific condition. For all other dogs, cardiac auscultation should occur at every veterinary visit, with echocardiography recommended when murmurs, arrhythmias, or clinical signs are detected.
What is a heart murmur, and does it mean my dog has heart disease?
A heart murmur is an abnormal sound caused by turbulent blood flow through the heart. Not all murmurs indicate disease. Low-grade (I-II) murmurs in young dogs are sometimes physiologic (innocent). However, any new murmur in a middle-aged or older dog should be evaluated with echocardiography to determine its cause and significance.
How much does an echocardiogram cost?
Echocardiography in dogs typically ranges from $300 to $600, depending on geographic location, whether the examination is performed by a general practitioner or a board-certified cardiologist, and whether Doppler assessment is included. For high-risk breeds, this cost should be considered an annual investment in early detection.
What is NT-proBNP and why should I test for it?
NT-proBNP is a protein released by heart muscle cells when they are under stress from volume or pressure overload. Elevated levels suggest the heart is working harder than normal and can indicate early cardiac disease before symptoms appear. It is available as a simple blood test and is particularly useful for screening breeds predisposed to dilated cardiomyopathy.
Can heart disease in dogs be prevented?
Most canine cardiac diseases have strong genetic components and cannot be fully prevented. However, early detection through screening allows earlier treatment initiation, which demonstrably extends survival time and quality of life. Maintaining ideal body weight, providing appropriate exercise, and supporting cardiovascular health through omega-3 fatty acids may support cardiac function.
What is the EPIC study and why does it matter?
The EPIC study (Boswood et al., 2016) was a landmark randomized controlled trial that demonstrated pimobendan delayed the onset of congestive heart failure by a median of 15 months in dogs with preclinical MMVD. It established that treating before symptoms appear produces meaningful benefit, which fundamentally depends on early detection through screening.
The Bottom Line
Heart disease is the second leading cause of death in dogs, and most cardiac conditions are asymptomatic in their early stages. Structured cardiac screening using auscultation, echocardiography, ECG, and NT-proBNP biomarkers can detect disease months to years before clinical signs appear. For high-risk breeds like the Cavalier King Charles Spaniel and Doberman Pinscher, breed-specific screening protocols with defined start ages and intervals are well-established. The EPIC study demonstrated that early treatment of preclinical valve disease extends the time to heart failure by over a year. That treatment window only exists if the disease is found before the dog starts coughing. Screening is the tool that opens it.